ID   OCI-AML3DNR
AC   CVCL_D6NF
RX   PubMed=21679421;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin).
CC   Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Arg882Cys (c.2644C>T); ClinVar=VCV000375882; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7910; NPM1; Simple; p.Trp288Cysfs*12 (c.860_863dupTCTG); ClinVar=VCV000013998; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1844 ! OCI-AML-3
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 10-09-24; Version: 1
//
RX   PubMed=21679421; DOI=10.1186/1471-2407-11-254; PMCID=PMC3146447;
RA   Grundy M., Seedhouse C., Russell N.H., Pallis M.;
RT   "P-glycoprotein and breast cancer resistance protein in acute myeloid
RT   leukaemia cells treated with the aurora-B kinase inhibitor
RT   barasertib-hQPA.";
RL   BMC Cancer 11:254.1-254.13(2011).
//